Traxens commended in the 2018 INPI Awards
Traxens, developer of a global solution for monitoring and coordinating multimodal transport, announced today that it has received a 2018 INPI prize in the Patent category. The award is for the intellectual property strategy it has adopted. Since 2012 Traxens has been developing on competitive international markets, with a strong focus on technology.
Traxens is one of the 12 SMEs and three research centers selected by this year's jury, and one of the three companies awarded in the Patents category. The award was presented by Eric Carreel, head of the jury in 2018.
'Traxens has brought containerized maritime transport into the digital age,' said Eric Carreel, president of the 2018 Awards. 'Given the high quality of the technologies developed by Traxens, I have no doubt that some will become industry standards, while others have already been licensed in other industrial sectors. Today, we want to congratulate the firm on its strategy, which is closely linked to the quality of its intellectual property.'
Following several years of large-scale testing, Traxens offers transport providers electronic boxes that are fixed to containers. These provide high value-added information, such as the container's position at sea and on land, the strength of any impacts, a record of doors being opened and closed or temperature variations.
'Our solution is currently being deployed in all the fleets owned by the MSC and CMA CGM shipping companies, and we are now adapting our product for SNCF to make it suitable for railway cars. We are also working with Daher to develop a connected briefcase for real-time monitoring of the transport of goods with very high added value,' said Jacques Delort, General Manager of Traxens. 'On the logistics 4.0 market, which is still in its infancy, we have been able to create ground-breaking technological solutions in partnership with eight public-sector laboratories. One of these is Inria, the French National Institute for Research in Computer Science and Automation. We own a number of international patents and we take a very active approach to combating infringements.'
Since they were set up in 1991, the INPI Awards have recognised and rewarded innovative companies and research centers that stand out because of their excellent intellectual property strategies. Expliseat, Wandercraft, Devialet, BlaBlaCar and Fermob are some of the award-winners in previous years, recognised for having made innovation into one of the mainsprings of their growth, adopting proactive and consistent industrial property policies.
About Traxens
Traxens offers logistics operators a
comprehensive solution for monitoring and coordinating multimodal
transport, making a crucial contribution to digital development in the
logistics sector. It has achieved this by creating both robust
electronic devices integrated into containers in transit and the shared
global platform that provides services with very high added value to all
logistics operators.
www.traxens.com
About INPI
In addition to its activities connected with
registering and issuing industrial property rights (patents, trademarks,
designs and models), the National Institute of Industrial Property
(INPI) promotes economic development through its work to raise awareness
of and highlight innovation and associated issues. The Institute
supports all innovators to transform their projects into concrete
achievements, and to derive value from their innovations.
A
self-financed public body reporting to the Ministry of Industrial
Property, INPI also plays an active role in producing and implementing
public policy in the domain of intellectual property, supporting
innovation and the competitiveness of businesses and combating
counterfeiting.
As holder of the records of all the industrial
property rights lodged in France and the data in the National Register
of Commerce and Companies, INPI provides access to over 7 million open,
free and reusable data items.
www.inpi.fr
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181212005248/en/
Contact information
Press:
Geraldine Sauniere
Director of Communications
g.sauniere@traxens.com
Tel:
+33 6 95 91 58 99
Tietoja julkaisijasta
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues26.3.2019 09:00:00 EET | Tiedote
Illumina (NASDAQ:ILMN) and the Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark partner to explore the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens. One of the first projects of its kind worldwide, the endeavor aims to acquire new knowledge in terms of the medical and biological understanding of special factors underlying the development of human neuropsychiatric diseases through the ages. Ultimately, the project may provide a new approach to the development of medicines and other therapeutic treatments for mental and neurological conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005867/en/ Where do brain disorders come from? In an effort to shed light on the role of microbes in the pathogenesis of neuropsychiatric illnesses, such as Alzheimer’s disease and schizophrenia, Professor Eske Willerslev and his team
Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA26.3.2019 02:00:00 EET | Tiedote
Earth Networks announced today the completion of the Philippines’ first nationwide severe weather monitoring and alerting network with associated software services for the Philippine Atmospheric, Geophysical, and Astronomical Services Administration (PAGASA), the National Meteorological and Hydrological Services (NMHS) agency of the Republic of the Philippines. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Initiated in 2017, and formally commissioned this week, the technology partnership between PAGASA and Earth Networks is the first of its kind in the Philippines and surrounding regions, powered by a network of total lightning sensors and real-time automatic weather stations for mesoscale monitoring. Installed and operated together with Philippines partner West Point Engineering, the 10-year program includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network On-the-ground weather monitoring via the Earth Networks W
Game of Thrones Winter is Coming™ Launches Worldwide26.3.2019 02:00:00 EET | Tiedote
Yoozoo Games, a leading game developer and publisher, today announced the global launch of Game of Thrones Winter is Coming™ , a real-time strategy PC browser game officially licensed by Warner Bros. Interactive Entertainment under license from HBO®. The game is now available in English, with additional languages to follow. HBO, Warner Bros. Interactive Entertainment and Yoozoo Games have collaborated to recreate Westeros on a massive scale, delivering an authentic and immersive multiplayer world laid out across the Seven Kingdoms – complete with major landmarks and castles from the epic TV series. The story begins immediately following the death of Eddard Stark, when the player emerges as a new Westeros lord or lady in his stead. Strategising starts in earnest in Game of Thrones Winter is Coming as players aim to build an impenetrable base, train a victorious army and recruit faithful followers from a pool of iconic characters. As players progress, they must continue to acquire the mi
bluebird bio Statement on European Regulatory Status of LentiGlobin™26.3.2019 01:40:00 EET | Tiedote
A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has been issued by the CHMP. If the CHMP’s opinion is issued it would then be reviewed by the European Commission (EC), which has the authority to grant approval for the use of LentiGlobin in the EU. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 23:30:00 EET | Tiedote
Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in
AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 22:50:00 EET | Tiedote
Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.
Tutustu uutishuoneeseemme